Japan Gastrointestinal Therapeutics Market Size & Outlook
Japan gastrointestinal therapeutics market, 2018-2030 (US$M)
Related Markets
Japan gastrointestinal therapeutics market highlights
- The Japan gastrointestinal therapeutics market generated a revenue of USD 1,971.9 million in 2022 and is expected to reach USD 2,763.6 million by 2030.
- The Japan market is expected to grow at a CAGR of 4.3% from 2023 to 2030.
- In terms of segment, branded was the largest revenue generating drug type in 2022.
- Generics is the most lucrative drug type segment registering the fastest growth during the forecast period.
Gastrointestinal therapeutics market data book summary
| Market revenue in 2022 | USD 1,971.9 million |
| Market revenue in 2030 | USD 2,763.6 million |
| Growth rate | 4.3% (CAGR from 2022 to 2030) |
| Largest segment | Branded |
| Fastest growing segment | Generics |
| Historical data | 2018 - 2021 |
| Base year | 2022 |
| Forecast period | 2023 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Branded, Generics |
| Key market players worldwide | AbbVie Inc, AstraZeneca PLC, Bausch Health Companies Inc, Takeda Pharmaceutical Co Ltd, Pfizer Inc, Bayer AG, Abbott Laboratories, Janssen Pharmaceuticals, Sun Pharmaceutical Industries, Cipla Ltd DR, Gilead Sciences Inc, Biogen Inc, Organon & Co Ordinary Shares |
Other key industry trends
- In terms of revenue, Japan accounted for 5.2% of the global gastrointestinal therapeutics market in 2022.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, Japan gastrointestinal therapeutics market is projected to lead the regional market in terms of revenue in 2030.
- India is the fastest growing regional market in Asia Pacific and is projected to reach USD 2,285.1 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Gastrointestinal Therapeutics Market Scope
Gastrointestinal Therapeutics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Japan gastrointestinal therapeutics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to gastrointestinal therapeutics market will help companies and investors design strategic landscapes.
Branded was the largest segment with a revenue share of 68.78% in 2022. Horizon Databook has segmented the Japan gastrointestinal therapeutics market based on branded, generics covering the revenue growth of each sub-segment from 2018 to 2030.
Japan held the largest market share in 2019, owing to the rise in product launches as well as approvals, growing number of R&D activities, high number of initiatives undertaken by market players & government organizations, and high prevalence of ulcerative colitis, Crohn’s disease, & GERD.
Growing number of drug approvals is another factor aiding growth in the country. For instance, in May 2019, Takeda Pharmaceutical Company Limited announced that the Ministry of Health, Labour and Welfare approved its drug Entyvio for treatment of Crohn’s disease.
The drug was also approved in 2018 for treatment of active ulcerative colitis. Thus, rise in the number of drug approvals for gastrointestinal diseases can be attributed to the largest share as well as future growth.
Reasons to subscribe to Japan gastrointestinal therapeutics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Japan gastrointestinal therapeutics market databook
-
Our clientele includes a mix of gastrointestinal therapeutics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan gastrointestinal therapeutics market, including forecasts for subscribers. This country databook contains high-level insights into Japan gastrointestinal therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Japan gastrointestinal therapeutics market size, by drug type, 2018-2030 (US$M)
Japan Gastrointestinal Therapeutics Market Share, 2022 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
